Workflow
广生堂(300436) - 2017 Q4 - 年度财报
CosunterCosunter(SZ:300436)2018-03-20 16:00

Financial Performance - The company's operating revenue for 2017 was ¥296,122,689.22, a decrease of 5.36% compared to ¥312,882,593.35 in 2016[16] - The net profit attributable to shareholders for 2017 was ¥33,565,301.69, down 49.46% from ¥66,413,000.53 in the previous year[16] - The net profit after deducting non-recurring gains and losses was ¥29,172,435.94, reflecting a 53.30% decline from ¥62,465,013.96 in 2016[16] - The basic earnings per share for 2017 was ¥0.24, a decrease of 48.94% compared to ¥0.47 in 2016[16] - The total assets at the end of 2017 amounted to ¥736,469,366.37, representing a 5.11% increase from ¥700,666,354.40 at the end of 2016[16] - The net assets attributable to shareholders at the end of 2017 were ¥552,048,099.73, a slight decrease of 0.06% from ¥552,361,356.97 in 2016[16] - The net cash flow from operating activities for 2017 was ¥71,468,005.80, down 3.22% from ¥73,842,321.31 in the previous year[16] - The weighted average return on equity for 2017 was 6.43%, a decrease of 6.13% from 12.56% in 2016[16] Revenue Breakdown - The company's total revenue for the year was approximately 296.12 million yuan, with a quarterly breakdown of 82.69 million yuan in Q1, 67.50 million yuan in Q2, 72.55 million yuan in Q3, and 73.38 million yuan in Q4[19] - The net profit attributable to shareholders for the year was approximately 33.56 million yuan, with Q1 contributing 20.40 million yuan, Q2 6.86 million yuan, Q3 2.17 million yuan, and Q4 4.14 million yuan[19] - The net cash flow from operating activities for the year was approximately 71.47 million yuan, with Q1 at 17.57 million yuan, Q2 32.52 million yuan, Q3 8.98 million yuan, and Q4 12.39 million yuan[19] - The sales revenue from the main antiviral products totaled approximately 296.12 million yuan, with the product "Aganidine" experiencing a 22.91% decline in sales compared to the previous year[24] - The sales revenue of the main product, Entecavir, was CNY 214.22 million, accounting for 72.34% of total revenue, with a decline of 4.01% compared to the previous year[38] Research and Development - The company invested CNY 75.33 million in R&D during the reporting period, representing 25.44% of operating revenue, indicating a strong commitment to innovation[31] - The R&D team consisted of 93 members, making up 16.64% of the total workforce, with 25.81% holding master's degrees or higher[40] - Research and development expenses amounted to ¥75,332,500, representing 25.44% of total revenue, an increase of 3.64% from 21.80% in the previous year[40] - The company is actively developing new drugs for hepatitis B, with significant progress reported in collaboration with WuXi AppTec[40] - Research and development efforts include the development of two new drugs for curing hepatitis B and one innovative drug for fatty liver, with significant progress reported in the GST-HG151 project targeting liver fibrosis[62] Market Strategy and Risks - The company faces potential risks and has outlined corresponding countermeasures in its future development outlook[5] - The company is experiencing increased competition in the nucleotide antiviral market, which may affect its market share and profitability if it fails to maintain a competitive edge in product quality and sales strategies[101] - The company is adjusting its sales model to comply with the two-invoice system, which has led to increased sales service fees, posing a risk to operating performance[103] - The company is preparing for the challenges and opportunities in the pharmaceutical industry, including regulatory changes and market competition[96] Shareholder and Dividend Information - The company plans to distribute a cash dividend of ¥1.00 per 10 shares to all shareholders[5] - The company's cash dividend distribution represents 100% of its distributable profits, reflecting a commitment to returning value to shareholders[107] - For 2017, the proposed cash dividend is 14.18 million yuan (including tax), which is 42.24% of the net profit attributable to ordinary shareholders[111] - The company has consistently maintained a cash dividend distribution plan over the past three years, with dividends paid out in May 2016 and March 2017[110] Subsidiaries and Investments - The company established several wholly-owned subsidiaries with a total registered capital of ¥45,000,000, enhancing its operational capacity[44] - The company has established a wholly-owned subsidiary for reproductive technology research, although specific financial details were not disclosed[81] - The company has established several subsidiaries during the reporting period, which are still in the setup phase and have not yet significantly impacted overall operations and performance[95] Governance and Compliance - The company has established a comprehensive governance structure, including a board of directors, supervisory board, and various committees, ensuring effective checks and balances[195] - The supervisory board strictly adheres to legal regulations and provides reasonable suggestions on major company matters, ensuring compliance and oversight of financial activities[196] - The company maintains independence from its controlling shareholder in business, personnel, assets, institutions, and finances, ensuring autonomous operational capabilities[199] Employee and Social Responsibility - The company has implemented measures to protect employee rights, including signing labor contracts and providing social insurance[147] - The company actively participates in social welfare activities, contributing to charity and educational support[148] - The total number of employees in the company is 559, with 542 in the parent company and 17 in major subsidiaries[189] Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion CNY[118] - New product launches are expected to contribute an additional 200 million CNY in revenue, with two new drugs set to enter the market in Q2 2018[116] - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[172]